ReviewDiabetology & metabolic syndrome2026
GLP-1 receptor agonists as multisystem therapies: from glycemic control to cardiorenal, neuroimmune, and metabolic disease.
Review in Diabetology & metabolic syndrome, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGlucagon-like peptide-1 receptor agonists (GLP-1RAs) were initially developed as incretin-based therapies for the management of type 2 diabetes mellitus. Over the past decade, robust clinical and mechanistic evidence has demonstrated that their therapeutic effects extend beyond glycemic control, leading to expanding use in obesity and cardiometabolic disease.
methodsThis narrative review synthesizes evidence from randomized controlled trials, cardiovascular and kidney outcome studies, meta-analyses, and real-world data, complemented by mechanistic and translational studies where relevant. Evidence across organ systems was critically appraised with attention to study design, outcome relevance, heterogeneity, and clinical certainty.
resultsGLP-1RAs consistently induce clinically meaningful weight loss and reduce major adverse cardiovascular events, while slowing the progression of chronic kidney disease in both diabetic and non-diabetic populations. These benefits are supported by large outcome trials and appear only partially attributable to improvements in glycemic control or body weight alone. In contrast, evidence supporting additional effects in metabolic liver disease and obstructive sleep apnea is moderate but evolving, whereas data on immune modulation, skeletal health, neuroprotection, and neuropsychiatric outcomes are largely derived from mechanistic, biomarker-based, observational, or preclinical studies and remain heterogeneous.
conclusionGLP-1 receptor agonists have transitioned from glucose-lowering therapies to cornerstone agents in cardiometabolic disease management. While their efficacy in obesity, cardiovascular risk reduction, and kidney protection is well established, proposed benefits in other organ systems should be interpreted cautiously and in the context of variable evidence strength. Future research should prioritize long-term safety, durability of benefit, and adequately powered trials designed to clarify disease-modifying potential beyond established cardiometabolic indications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.